Details of the Drug Reposition

General Information of This Drug (ID: DM0T3YH)

• Drug Name: Indinavir (DM0T3YH)
• Synonyms: Crixivan; IDV; Indinavir [USAN]; L 735524; Crixivan (TM); Crixivan (TN); L-735 524; L-735524; MK-639; Propolis+Indinavir; RS-253; L-735,524; Indinavir, Sulfate (1:1); Indinavir (*1:1 Sulfate salt*); N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE; Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide; (1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide; (2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
• Therapeutic Class: Anti-HIV Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Human immunodeficiency virus infection	DISRNAI4	1C62	Approved	[1]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
HIV infectious disease	DISO97HC	N.A.	Discontinued in Phase 2	[2]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Investigative	[3]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 200626.
• [2] Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients
• [3] Old Drugs for Newly Emerging Viral Disease, COVID-19: Bioinformatic Prospective